Firebrick Pharma Unveils Nasodine Throat Spray for Singapore Export

Firebrick Pharma Expands Nasodine Range

Firebrick Pharma Limited (ASX – FRE) has announced the commencement of manufacturing for its latest product, Nasodine Throat Spray, marking a significant step in the company’s strategy to broaden its portfolio of povidone-iodine antiseptic treatments. This new formulation, designed specifically for sore throat relief, is set for export starting November 2025, with Singapore as the initial market.

The Nasodine Throat Spray is a 1% povidone-iodine solution delivered in a convenient spray format, distinguishing itself from traditional throat gargles by eliminating the need to spit out excess liquid. This innovation addresses common user concerns such as staining and inconvenience, offering a more targeted and user-friendly treatment option.

Regulatory and Market Launch Details

While the Therapeutic Goods Administration (TGA) in Australia has granted export approval for the product, local sales within Australia remain restricted at this stage. Firebrick has partnered with Probiotec, an Australian manufacturer, to produce the initial batch of the throat spray. The product’s first commercial introduction will be in Singapore, where it can be marketed as an antiseptic without requiring additional local regulatory approval.

In Singapore, Firebrick’s licensing partner, Innorini Life Sciences, plans to begin marketing the throat spray to hospitals and healthcare professionals in December 2025, with retail availability anticipated by mid-2026. This phased rollout reflects a strategic approach to build clinical acceptance before wider consumer adoption.

Strategic Implications and Future Outlook

The launch of Nasodine Throat Spray follows the earlier introduction of Nasodine Nasal Spray, which debuted in Singapore in 2024 and has since expanded into markets including the United States, Fiji, and Brunei. Firebrick’s commitment to developing a range of Nasodine-branded products signals its ambition to establish a strong foothold in the antiseptic treatment segment globally.

By focusing initially on export markets with favorable regulatory environments, Firebrick is positioning itself to capitalize on international demand while navigating the complexities of domestic approvals. The company’s approach suggests a long-term vision of incremental product launches that leverage existing brand recognition and licensing partnerships.